Inhaled Nitric Oxide for Modulation of Ischemia–Reperfusion Injury in Lung Transplantation

Botha, Phil; Jeyakanthan, M.; Rao, Jagan; Fisher, Andrew J.; Prabhu, Mahesh; Dark, John H.; Clark, Stephen

doi:10.1016/j.healun.2007.08.008

Cited by 69 publications

(40 citation statements)

References 35 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found no clinical benefit and a trend toward increased proinflammatory cytokines in the treated lungs. 23 This is further evidence that nitric oxide may provide no benefit in lung transplantation from brain-dead donors irrespective of the time of administration.…”

Section: Discussionmentioning

confidence: 92%

Treatment of the brain-dead lung donor with aprotinin and nitric oxide

Avlonitis

Wigfield

Kirby

et al. 2010

The Journal of Heart and Lung Transplantation

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 92%

Treatment of the brain-dead lung donor with aprotinin and nitric oxide

Avlonitis

Wigfield

Kirby

et al. 2010

The Journal of Heart and Lung Transplantation

Self Cite

View full text Add to dashboard Cite

“…Its role in inflammation, tissue injury, apoptosis, and cell defense is currently being investigated [11,16,17,41,64]. NO appears to be a key link between ischemia/reperfusion injury and the rate of tissue repair [7,42,46]. In fact, alterations in NO generation appear to underpin the interrelationship of endothelial function and inflammation, with several potential protective roles in inflammatory response and ischemia.…”

Section: Inhaled Nomentioning

confidence: 99%

Review of Inhaled Nitric Oxide in the Pediatric Cardiac Surgery Setting

Checchia

Bronicki

Goldstein³

2012

Pediatr Cardiol

View full text Add to dashboard Cite

Surgical intervention for congenital heart disease (CHD) can be complicated by pulmonary hypertension (PH), which increases morbidity, mortality, and medical burden. Consequently, postoperative management of PH is an important clinical consideration to improve outcomes. Inhaled nitric oxide (iNO) is a widely accepted standard of care for PH and has been studied in the context of cardiac surgery for CHD. However, large randomized, double-blind, placebo-controlled, multicenter clinical trials in pediatric patients are limited. This review will provide an overview of the clinical studies in this setting and will discuss general treatment considerations to facilitate a better understanding of the clinical use of iNO for PH after pediatric cardiac surgery.

show abstract

“…Sin embargo, los resultados contradictorios aportados por otros autores, junto con la ausencia de estudios clínicos randomizados, impide que su uso sea generalizado. Estaría indicado en casos seleccionados de hipoxemia grave, acompañada de hipertensión arterial pulmonar 34,35 .…”

Section: Tratamientounclassified